1662 related articles for article (PubMed ID: 21910698)
21. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points.
Puig L; López A; Vilarrasa E; García I
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1633-53. PubMed ID: 24033851
[TBL] [Abstract][Full Text] [Related]
22. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan.
Igarashi A; Kuwabara H; Fahrbach K; Schenkel B
J Dermatolog Treat; 2013 Oct; 24(5):351-5. PubMed ID: 22632451
[TBL] [Abstract][Full Text] [Related]
23. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
[TBL] [Abstract][Full Text] [Related]
25. Erythrodermic psoriasis: current and future role of biologicals.
Stinco G; Errichetti E
BioDrugs; 2015 Apr; 29(2):91-101. PubMed ID: 25752640
[TBL] [Abstract][Full Text] [Related]
26. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab for the treatment of moderate to severe psoriasis.
Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
[TBL] [Abstract][Full Text] [Related]
28. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
29. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
30. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
[TBL] [Abstract][Full Text] [Related]
31. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
[TBL] [Abstract][Full Text] [Related]
32. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials.
Farhi D
Drugs Today (Barc); 2010 Apr; 46(4):259-64. PubMed ID: 20502723
[TBL] [Abstract][Full Text] [Related]
33. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Loos AM; Liu S; Segel C; Ollendorf DA; Pearson SD; Linder JA
J Am Acad Dermatol; 2018 Jul; 79(1):135-144.e7. PubMed ID: 29438757
[TBL] [Abstract][Full Text] [Related]
35. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
[TBL] [Abstract][Full Text] [Related]
36. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
Papp KA; Dekoven J; Parsons L; Pirzada S; Robern M; Robertson L; Tan JK
J Cutan Med Surg; 2012; 16(3):153-68. PubMed ID: 22713438
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy of biologics in psoriasis: a review.
Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.
Bansback N; Sizto S; Sun H; Feldman S; Willian MK; Anis A
Dermatology; 2009; 219(3):209-18. PubMed ID: 19657180
[TBL] [Abstract][Full Text] [Related]
39. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
40. Advancements in the treatment of psoriasis: role of biologic agents.
Rich SJ; Bello-Quintero CE
J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
